Neptune Technologies & Bioressources Inc  

(Public, TSE:NTB)   Watch this stock  
Find more results for NTB
2.28
-0.04 (-1.72%)
Mar 4 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 2.24 - 2.34
52 week 1.26 - 3.15
Open 2.34
Vol / Avg. 15,876.00/19,231.00
Mkt cap 170.95M
P/E     -
Div/yield     -
EPS -0.25
Shares 74.98M
Beta 1.80
Inst. own     -
May 19, 2015
Q4 2015 Neptune Technologies & Bioressources Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 10, 2015
Neptune Technologies & Bioressources Inc at ROTH Conference - 7:30PM EDT - Add to calendar
Jan 14, 2015
Q3 2015 Neptune Technologies & Bioressources Inc Earnings Call
Jan 13, 2015
Neptune Technologies & Bioressources Inc at OneMedForum SF
Jan 13, 2015
Q3 2015 Neptune Technologies & Bioressources Inc Earnings Release
  

Key stats and ratios

Q4 (Nov '14) 2014
Net profit margin 1.56% -114.06%
Operating margin -123.13% -112.41%
EBITD margin - -103.69%
Return on average assets 0.26% -26.21%
Return on average equity -7.96% -31.30%
Employees 111 -
CDP Score - -

Address

545 Prom du Centropolis Suite 100
LAVAL, QC H7T 0A3
Canada
+1-450-6872262 (Phone)
+1-450-6872272 (Fax)

Website links

Description

Neptune Technologies & Bioressources Inc. (Neptune) is a biotechnology company. The Company is engaged primarily in the development, manufacture and commercialization of marine-derived omega-3 polyunsaturated fatty acids (PUFAs). The Company operates in three segments: Neptune, Acasti Pharma Inc. and Acasti Pharma Inc. Its Neptune produces and commercializes nutraceutical products. Its Acasti Pharma Inc. develops and commercializes pharmaceutical applications for cardiovascular diseases. Its NeuroBioPharm Inc. develops and commercializes pharmaceutical applications for neurological diseases. It produces omega-3 PUFAs through its patented process of extracting oils from Antartic krill, which omega-3 PUFAs are then principally sold as bulk oil to Neptune�s distributors who commercialize them under their private label primarily in the United States, European and Australian nutraceutical markets. The Company�s products include Neptune Krill Oil (NKO) and ECOKRILL Oil (EKO).

Officers and directors

Pierre Fitzgibbon Chairman of the Board
Age: 59
James Stuart Hamilton President, Chief Executive Officer, Director
Andre Godin Chief Financial Officer
Michel Timperio Senior Vice President of Sales - Global Sales
Wael Massrieh Vice President - Scientific Affairs
Fotini Sampalis M.D., Ph.D. Chief Global Strategy Officer
Ronald Denis Director
Harlan W. Waksal M.D. Director
Age: 60
Valier Boivin Independent Director
Adrian Montgomery Independent Director